Different colored lines ranging from red to blue indicate the trajectories of Fyn proteins within a neuron.

Researchers used super-resolution microscopy to observe the movements of individual Fyn proteins within mouse hippocampal dendritic spines.

credit: Frederic Meunier and Ramón Martínez-Mármol

Tracking the movement of individual proteins in dementia

A dementia-associated tau mutation promotes unusual clustering of Fyn, a protein important for learning and memory.
Hannah Thomasy
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Even though researchers have been studying the tau protein for decades, the molecular mechanisms by which tau contributes to Alzheimer’s disease and other forms of dementia are still not fully understood. Frederic Meunier, a neurobiologist at the University of Queensland, thinks that some of tau’s toxicity relates to its interactions with an enzyme called Fyn.

“Fyn is a very important enzyme,” said Meunier. “It’s linked to memory in many different ways." Fyn also seems to play a role in Alzheimer’s disease (1).

Under normal circumstances, Fyn moves around inside a neuron quite quickly. “If Fyn was the size of a person, it would travel about 250 kilometers per hour, just bouncing everywhere,” said Meunier. However, Fyn can also cluster in the postsynaptic regions of neurons. Meunier wanted to understand the molecular factors that allowed this fast-moving enzyme to accumulate in such small, specific regions of the neuron, as well as how tau affects the movement of Fyn enzymes at the nanoscale level.

Fyn is a very important enzyme. It’s linked to memory in many different ways. 
- Frederic Meunier, the University of Queensland

In order to answer these questions, Meunier and Ramón Martínez-Mármol, a research fellow at the University of Queensland, used super-resolution microscopy to track individual Fyn proteins as they bounced around inside cultured hippocampal neurons (2).

In normal neurons, they found that when Fyn switched from a tight, closed shape to a more open form, it promoted Fyn clustering in the dendrites. When the neurons expressed a mutant form of the tau protein that associates with dementia, however, Fyn clustering increased above normal levels.

The team then investigated the mechanisms through which tau caused this abnormal clustering. Previous work showed that tau can form biomolecular condensates, or membraneless droplets, inside the cell; the mutant form of tau has an even higher likelihood of forming these condensates (3). The team thought that these mutant tau droplets might sequester Fyn enzymes, trapping them together and resulting in the abnormally high clustering. And indeed, said Meunier, “we showed that if you dissolve this biomolecular condensate, this extra clustering is gone.”

This is important because while a certain level of Fyn seems to be required for learning and memory, hyperactivity of Fyn can be toxic, contributing to neuronal dysfunction and death in dementia (1). By targeting tau biomolecular condensates, researchers might be able to bring Fyn clustering back down to normal levels, which might help treat or prevent some forms of dementia.

While there’s still a lot of work to be done, “we think that there's definitely some scope here to design drugs,” said Meunier.

References

  1. Nygaard, H. B., van Dyck, C. H. & Strittmatter, S. M. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alz Res Therapy  6, 8 (2014).
  2. Martínez-Mármol, R. et al. Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates. Mol Psychiatry  28, 946–962 (2023).
  3. Kanaan, N. M., Hamel, C., Grabinski, T. & Combs, B. Liquid-liquid phase separation induces pathogenic tau conformations in vitro. Nat Commun  11, 2809 (2020).

About the Author

  • Hannah Thomasy
    Hannah joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in 2020.

Related Topics

Published In

November 2023 magazine issue front cover
Volume 19 - Issue 11 | November 2023

November 2023

November 2023 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue